$324 Thousand is the total value of Krensavage Asset Management, LLC's 12 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Sell | UNITED THERAPEUTICS CORP | $53,407 | -99.9% | 192,048 | -4.2% | 16.50% | +23.5% |
| BIIB | Sell | BIOGEN INC | $49,016 | -99.9% | 177,004 | -4.1% | 15.14% | -3.5% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $43,364 | -99.9% | 60,103 | -1.3% | 13.40% | +0.3% |
| ALKS | Sell | ALKERMES PLC | $36,629 | -99.9% | 1,401,783 | -0.7% | 11.32% | +12.8% |
| EXEL | Buy | EXELIXIS INC | $34,294 | -99.9% | 2,138,039 | +17.4% | 10.60% | +16.5% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $27,671 | -99.9% | 594,818 | +0.9% | 8.55% | -12.2% |
| Sell | EMBECTA CORP | $25,737 | -99.9% | 1,017,657 | -0.6% | 7.95% | -15.3% | |
| CAH | Sell | CARDINAL HEALTH INC | $25,578 | -99.9% | 332,749 | -1.2% | 7.90% | +10.5% |
| TARO | Buy | TARO PHARMACEUTICAL INDUS | $18,721 | -99.9% | 644,664 | +11.0% | 5.78% | +4.3% |
| EGRX | Sell | EAGLE PHARMACEUTICALS INC | $3,356 | -99.9% | 114,825 | -5.2% | 1.04% | +1.8% |
| KOD | Sell | KODIAK SCIENCES INC | $3,319 | -99.9% | 463,598 | -1.2% | 1.03% | -11.3% |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $2,552 | -99.9% | 345,290 | +10.6% | 0.79% | -19.7% |
| NXTC | Exit | NEXTCURE INC | $0 | – | -31,298 | -100.0% | -0.03% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -31,913 | -100.0% | -3.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.